ConcertAI CEO Talks COVID-19 & The De-Risking of Technology to Keep Trials Moving


Nothing like it had ever happened before – a global slowdown in new study starts and a massive decrease in trial accruals for open studies. The turn of events was a shock for sponsors and providers. Sudden disruptions on that scale rarely hit multiple players in an ecosystem at the same time. But that’s exactly what happened at the intersection of clinical care and clinical development during the pandemic. Researchers and clinicians were forced to change how they operated trials, and technological solutions that researchers had been slowly exploring for trials were suddenly adopted at rapid speeds.

We recently spoke with Jeff Elton, CEO of ConcertAI, a healthcare and life sciences AI and real-world data (RWD) solutions provider. Elton is acutely aware of the impact that this rapid adoption of technology has had on trials through the work ConcertAI does to support and enhance trials. Here are his thoughts on what’s to come.

Read More